Lb Pharmaceuticals (LBRX) Operating Expenses (2024 - 2026)

Lb Pharmaceuticals has reported Operating Expenses for 3 years, with the latest figure at $22.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 243.82% year-over-year to $22.1 million; the trailing twelve-month figure through Mar 2026 stood at $47.6 million (changed N/A YoY), and the FY2025 full-year result was $30.4 million, down 53.1% from the prior year.
• Operating Expenses for Q1 2026 stood at $22.1 million, up from $13.9 million in the prior quarter.
• The five-year high for Operating Expenses was $22.1 million in Q1 2026, with the low at $5.2 million in Q3 2025.
• Average Operating Expenses over 3 years is $11.5 million, with a median of $10.1 million recorded in 2025.
• Year-over-year, Operating Expenses plunged 67.38% in 2025 and soared 243.82% in 2026.
• Tracing LBRX's Operating Expenses over 3 years: stood at $5.5 million in 2024, then surged by 150.41% to $13.9 million in 2025, then surged by 59.37% to $22.1 million in 2026.
• The last three Operating Expenses figures came in at $22.1 million (Q1 2026), $13.9 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.

Peer Comparison